Clarity Pharmaceuticals (ASX:CU6) has announced that Allison Rossiter has joined its board as an independent Non-Executive Director, a move the clinical‑stage radiopharmaceutical company said will create a majority of independent directors as it advances toward commercialisation.
Rossiter brings 25 years of global healthcare leadership across diagnostics, pharmaceuticals and medical technology, having held senior roles across all three Roche divisions and most recently serving as Country President for Australia and New Zealand at Novartis.
Clarity’s Executive Chairperson, Dr Alan Taylor, said, "We are very pleased to welcome Ali to the Board as an independent Non‑Executive Director. The depth and breadth of her experience in the industry, in addition to her leadership expertise across three continents, are unique in the field, and we are honoured to have this calibre of talent on our Board. Ali’s extensive knowledge of the commercial diagnostic space in particular will be invaluable to Clarity during this exciting phase of commercialisation of two of our diagnostic products into the oncology market."
Rossiter said her initial focus will be on SAR‑bisPSMA, noting its performance versus current standards and the market opportunity: "Clarity is entering a pivotal phase in its evolution — progressing from proprietary innovation at the bench to the cusp of commercialisation in a significant global market. I am delighted to join the Board at such an important time for the Company. My initial focus will be on the lead diagnostic, SAR‑bisPSMA, which continues to demonstrate exceptional efficacy compared with current standard‑of‑care. It is remarkable that the multi‑billion‑dollar PSMA imaging market remains dominated by products with such low sensitivity — something almost unheard of in diagnostics. With strong and growing data supporting commercialisation pathways in the US, and a highly capable team with world‑class expertise, Clarity is well positioned to lead this category."
Rossiter also emphasised the personal significance of the work, "The strength and consistency of the SAR‑bisPSMA data underscore the potential for a meaningful step‑change in prostate cancer imaging. The opportunity to contribute to the development of more accurate, reliable and accessible diagnostics is one I take very seriously."
She added, "This work is also personally significant. My family has been directly impacted by prostate cancer — my father lives with the disease, and the future risk to my three sons is very real. I am hopeful that the next generation of diagnostic and therapeutic innovation will deliver substantial improvements for patients, families and clinicians. I am proud to join Clarity at this stage of its journey and to support the advancement of better diagnostics and therapies for people living with cancer."
